Regulation of Survivin Gene Expression in Stem Cell and Cancer Stem Cells and Emphasis Approach
Abstract
Background: Gene expression regulation is a method that cells utilize to enhance or decrease the output of specific genes (proteins or RNA). In biological and medical research such as cancer, gene expression is routinely observed. Survivin is a protein that is commonly produced in cancer cells and has the potential to be investigated. Survivin is a unique protein with two distinct roles: preventing apoptosis and regulating cell division. The inhibitory apoptosis protein (IAP) family includes the smallest member. Furthermore, Survivin is highly expressed in a variety of somatic stem cell types as well as human embryonic stem cells. Comparing most cancer cells to normal tissues, survivin is also present in higher amounts. This review aimed to examine the properties of survivin, how it is expressed in cancerous and normal stem cells, how it affects proliferation or apoptosis, and how to block their expression.
Methods: The literature on the regulation of survivin expression in cancer cells and stem cells that was published in English between 2014 and 2024 is reviewed in this study. For articles, we looked through PubMed, Scopus, and the Google Scholar database. In order to support the theories, publications from before 2014 were also tracked down.
Results: Molecular mechanism studies indicate that survivin participates in numerous signaling pathways, including MAPK, STAT3, b-catenin, Wnt, Notch, and others, and also controls the progression of the cell cycle and cytokinesis. Several elements, such as signaling pathway blockage siRNA technology, and CRISPR/Cas9 system have been discovered to aid in the induction of cancer cell death.
Conclusion: Survivin is linked to several cancer survival-related pathways, contributing to carcinogenesis. Its expression is associated with treatment resistance, tumor development, and poor prognosis.
Keywords
DOI: 10.33371/ijoc.v19i1.1142
Article Metrics
Abstract View: 206, 
PDF Download: 128
References
Bell JT, Pai AA, Pickrell JK, et al. Correction: DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011;12:1–13.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Nakaya T, Ogawa S, Manabe I, et al. KLF5 regulates the integrity and oncogenicity of intestinal stem cells. Cancer Res. 2014;74:2882–91.
Mull AN, Klar A, Navara CS. Differential localization and high expression of SURVIVIN splice variants in human embryonic stem cells but not in differentiated cells implicate a role for SURVIVIN in pluripotency. Stem Cell Res. 2014;12:539–49.
Zhang L, Yan R, Zhang Q, et al. Survivin, a key component of the Wnt/β-catenin signaling pathway, contributes to traumatic brain injury-induced adult neurogenesis in the mouse dentate gyrus. Int J Mol Med. 2013;32:867–75.
Kahn M, Kim Y. The role of the Wnt signaling pathway in cancer stem cells: prospects for drug development. Res Reports Biochem. 2014;1.
Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022;21:1–34.
Kumar V, Vashishta M, Kong L, et al. The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. Front Cell Dev Biol. 2021;9:1–24.
Wuputra K, Ku CC, Wu DC, et al. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. J Exp Clin Cancer Res. 2020;39:1–24.
Cui X, Shen D, Kong C, et al. NF-κ B suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo. Sci Rep. 2017;7:1–13.
Yang X, Yao J, Luo Y, et al. P38 MAP kinase mediates apoptosis after genipin treatment in non-small-cell lung cancer H1299 cells via a mitochondrial apoptotic cascade. J Pharmacol Sci. 2013;121:272–81.
Zhang Y, Chen HX, Zhou SY, et al. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Mol Cancer. 2015;14:1–18.
Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci. 2013;126:2135–40.
Zou B, Zhou XL, Lai SQ, et al. Notch signaling and non-small cell lung cancer (review). Oncol Lett. 2018;15:3415–21.
Budak M. Methylation of The Promoter of Survivin Gene May Affect Immunohistochemical Expression of Survivin Protein in Lung Cancers. Cerrahpasa Med J. 2019;43:44–9.
Cui X, Shen D, Kong C, et al. NF-κ B suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo. Sci Rep. 2017;7:1–13.
Beishline K, Azizkhan-Clifford J. Sp1 and the ‘hallmarks of cancer’. FEBS J. 2015;282:224–58.
Warrier NM, Agarwal P, Kumar P. Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics. Stem Cell Rev Reports. 2020;16:828–52.
Xu Q, Liu M, Xu N, et al. Variation in Sp1 binding sites correlates with expression of survivin in breast cancer. Mol Med Rep. 2014;10:1395–9.
Li F. Survivin Study: What Is the Next Wave? J Cell Physiol. 2003;197:8–29.
Jin PY, Zheng ZH, Lu HJ, et al. Roles of β-catenin, TCF-4, and survivin in nasopharyngeal carcinoma: Correlation with clinicopathological features and prognostic significance. Cancer Cell Int. 2019;19:1–12.
Lee KS, Lee MG, Nam KS. Evaluation of the antimetastatic and anticancer activities of morin in HER2‑overexpressing breast cancer SK‑BR‑3 cells. Oncol Rep. 2021 Jul;46(1):126.
Broekgaarden M, Weijer R, van Gulik TM, et al. Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev. 2015;34:643–90.
Chen Y, Li D, Liu H, et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol Ther. 2011;11:14–21.
Siddiqa A, Long LM, Li L, et al. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer. 2008;8:1–8.
Qiu L, Di W, Jiang Q, et al. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol. 2005;27:1441–8.
McNeish IA, Lopes R, Bell SJ, et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res. 2005;302:69–82.
Di C, Syafrizayanti, Zhang Q, et al. Function, clinical application, and strategies of Pre-mRNA splicing in cancer. Cell Death Differ. 2019;26:1181–94.
Wanandi SI, Limanto A, Yunita E, et al. In silico and in vitro studies on the anti-cancer activity of andrographolide targeting survivin in human breast cancer stem cells. PLoS One. 2020;15(11):e0240020.
Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004;114:1117–27.
Wang H, Holloway MP, Ma L, et al. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem. 2010;285:36129–37.
Zhang Z, Wang T, Liu Z, et al. Small interfering RNA targeting of the survivin gene inhibits human tumor cell growth in vitro. Exp Ther Med. 2017;14:35–42.
Martínez-García D, Pérez-Hernández M, Korrodi-Gregório L, et al. The natural-based antitumor compound T21 decreases survivin levels through potent stat3 inhibition in lung cancer models. Biomolecules. 2019;9:25–30.
Voges Y, Michaelis M, Rothweiler F, et al. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance. Cell Death Dis. 2016;7:1–11.
Syahrani RA, Yunita E, Wanandi SI. Suppression of rotenone-treated human breast cancer stem cell survival using survivin inhibitor YM155 is associated to oxidative stress modulation. Asian Pacific J Cancer Prev. 2020;21:2631–7.
Cheng SM, Chang YC, Liu CY, et al. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Br J Pharmacol. 2015;172: 214–34.
Narimani M, Sharifi M, Jalili A. Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1. Blood Lymphat Cancer. 2019;9:53-61.
Narimani M, Sharifi M, Hakhamaneshi MS, et al. BIRC5 gene disruption via CRISPR/cas9n platform suppress acute myelocytic leukemia progression. Iran Biomed J. 2019;23:369–78.
Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, et al. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res. 2011;17:3716–26.
DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996;14(4):457-60.
Lopergolo A, Tavecchio M, Lisanti S, et al. Chk2 phosphorylation of survivin-ΔEx3 contributes to a DNA damage-sensing checkpoint in cancer. Cancer Res. 2012;72:3251–9.
Sampath J, Pelus L, Sampath J, et al. Alternative Splice Variants of Survivin as Potential Targets in Cancer. Curr Drug Discov Technol. 2007;4:174–91.
Khan S, Bennit HF, Wall NR. The emerging role of exosomes in survivin secretion. Histol Histopathol. 2015;30:43–50.
Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.
Chandele A, Prasad V, Jagtap JC, et al. Upregulation of Survivin in G2/M Cells and Inhibition of Caspase 9 Activity Enhances Resistance in Staurosporine-Induced Apoptosis. Neoplasia. 2004;6:29–40.
Goldar S, Khaniani MS, Derakhshan SM, et al. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pacific J Cancer Prev. 2015;16:2129–44.
Kitagawa M, Lee SH. The chromosomal passenger complex (CPC) as a key orchestrator of orderly mitotic exit and cytokinesis. Front Cell Dev Biol. 2015;3:1–14.
Chu Y, Yao PY, Wang W, et al. Aurora B kinase activation requires survivin priming phosphorylation by PLK1. J Mol Cell Biol. 2011;3:260–7.
Filion TM, Qiao M, Ghule PN, et al. Survival responses of human embryonic stem cells to DNA damage. J Cell Physiol. 2009;220:586–92.
Gil-Kulik P, Krzyżanowski A, Dudzińska E, et al. Potential Involvement of BIRC5 in Maintaining Pluripotency and Cell Differentiation of Human Stem Cells. Oxid Med Cell Longev. 2019;2019:8727925.
Singh P, Fukuda S, Liu L, et al. Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function. Stem Cells. 2018;36:123–9.
Ejarque M, Ceperuelo-Mallafré V, Serena C, et al. Survivin, a key player in cancer progression, increases in obesity and protects adipose tissue stem cells from apoptosis. Cell Death Dis. 2017;8:e2802.
Labarrade F, Botto JM, Domloge N. CRM1 and chromosomal passenger complex component survivin are essential to normal mitosis progress and to preserve keratinocytes from mitotic abnormalities. Int J Cosmet Sci. 2016;38:452–61.
Atena M, Reza AM, Mehran G. A Review on the Biology of Cancer Stem Cells. Stem Cell Discov. 2014;04:83–9.
Fukuda S, Abe M, Onishi C, et al. Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol. 2011;2011:946936.
Guvenc H, Pavlyukov MS, Joshi K, et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for survivin-ran protein complex. Clin Cancer Res. 2013;19: 631–42.
Di Stefano AB, Iovino F, Lombardo Y, et al. Survivin is regulated by interleukin-4 in colon cancer stem cells. J Cell Physiol. 2010;225:555–61.
Li W, Lee MR, Choi EH, et al. Clinicopathologic significance of survivin expression in relation to CD133 expression in surgically resected stage II or III colorectal cancer. J Pathol Transl Med. 2017;51:17–23.
Sam S, Sam MR, Esmaeillou M, et al. Effective Targeting Survivin, Caspase-3 and MicroRNA-16-1 Expression by Methyl-3-pentyl-6-methoxyprodigiosene Triggers Apoptosis in Colorectal Cancer Stem-Like Cells. Pathol Oncol Res. 2016;22:715–23.
Kim ST, Sohn I, Do IG, et al. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Cancer Genomics and Proteomics. 2014;11:259–66.
Yie SM, Lou B, Ye SR, et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15:3073–82.
Liao CP, Adisetiyo H, Liang M, et al. Cancer Stem Cells and Microenvironment in Prostate Cancer Progression. Horm Cancer. 2010;1:297–305.
Luo Y, Liu T, Fei W, et al. Correlation between SOX2 and Survivin clinical features in patients with salivary adenoid cystic carcinoma. J Infect Public Health. 2019;12:847-53.
Zhang J, Chen X, Bian L, et al. CD44 + /CD24 + -Expressing Cervical Cancer Cells and Radioresistant Cervical Cancer Cells Exhibit Cancer Stem Cell Characteristics. Gynecol Obstet Invest. 2019;84:174–82.
Kim J, Ahn S, Kim K, et al. Prognostic significance of survivin expression and combined analysis with cancer stem cell and epithelial–mesenchymal transition-related markers in patients with rectal cancer undergoing preoperative chemoradiotherapy. Anticancer Res. 2018;38:6881–9.
Reviejo M, Soto M, Lozano E, et al. Impact of alternative splicing on mechanisms of resistance to anticancer drugs. Biochem Pharmacol. 2021;193:114810.
Morshedzadeh F, Ghanei M, Lotfi M, et al. An Update on the Application of CRISPR Technology in Clinical Practice. Mol Biotechnol. 2024;66:179–7.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
